drugset
drugset / Trial / NCT07025239

QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer

NCT07025239 ↗

Phase 3 Not yet recruiting 430 enrolled Qilu Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of QL1706 Injection in combination with bevacizumab and XELOX compared with placebo in combination with bevacizumab and XELOX for first-line treatment in patients with unresectable mCRC.

Timeline

Start
2025-07
Primary completion
2028-07
Completion
2029-07

Drugs

EvaluationDrugModalityDoseRoute
Subject QL1706 Monoclonal antibody 5 mg/kg Intravenous
Background Bevacizumab Monoclonal antibody 7.5 mg/kg Intravenous
Background Capecitabine Small molecule 1000 mg/m2 Oral
Background Oxaliplatin Small molecule 130 mg/m2 Intravenous

Indications

colorectal cancer